Literature DB >> 27888417

Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.

María Rosario Blasco1, Antonio Ramos2, Celia García Malo2, Antonio García-Merino2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27888417     DOI： 10.1007/s00415-016-8306-x

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   6.682


× No keyword cloud information.
  7 in total

Review 1.  Acute infusion reactions induced by monoclonal antibody therapy.

Authors:  Enrico Maggi; Alessandra Vultaggio; Andrea Matucci
Journal:  Expert Rev Clin Immunol       Date:  2011-01       Impact factor: 4.473

Review 2.  Cytokine-release syndrome: overview and nursing implications.

Authors:  Sheila Breslin
Journal:  Clin J Oncol Nurs       Date:  2007-02       Impact factor: 1.027

3.  Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

Authors:  T Moreau; A Coles; M Wing; J Isaacs; G Hale; H Waldmann; A Compston
Journal:  Brain       Date:  1996-02       Impact factor: 13.501

4.  Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

Authors:  M G Wing; T Moreau; J Greenwood; R M Smith; G Hale; J Isaacs; H Waldmann; P J Lachmann; A Compston
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

Review 5.  Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.

Authors:  Tobias Ruck; Stefan Bittner; Heinz Wiendl; Sven G Meuth
Journal:  Int J Mol Sci       Date:  2015-07-20       Impact factor: 5.923

Review 6.  Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.

Authors:  Hans-Peter Hartung; Orhan Aktas; Alexey N Boyko
Journal:  Mult Scler       Date:  2014-10-24       Impact factor: 6.312

7.  Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS.

Authors:  Katja Thomas; Judith Eisele; Francisco Alejandro Rodriguez-Leal; Undine Hainke; Tjalf Ziemssen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-04-29
  7 in total
  5 in total

Review 1.  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors:  Babak Soleimani; Katy Murray; David Hunt
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

2.  Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.

Authors:  Jessica Frau; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Luigina Musu; Eleonora Cocco
Journal:  J Neurol       Date:  2019-03-12       Impact factor: 4.849

Review 3.  Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.

Authors:  Nik Krajnc; Gabriel Bsteh; Thomas Berger; Jan Mares; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2022-04-04       Impact factor: 6.088

Review 4.  Inhaled antibodies: Quality and performance considerations.

Authors:  Anthony James Hickey; Ian Edward Stewart
Journal:  Hum Vaccin Immunother       Date:  2021-06-30       Impact factor: 4.526

5.  Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report.

Authors:  Aija Zuleron Myro; Gisle Bjerke; Svetozar Zarnovicky; Trygve Holmøy
Journal:  BMC Pharmacol Toxicol       Date:  2018-11-19       Impact factor: 2.483
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.